[go: up one dir, main page]

DE60034947D1 - Virusähnliche partikel, vorbereitung und verwendung in screening und funktionelle genomanwendung - Google Patents

Virusähnliche partikel, vorbereitung und verwendung in screening und funktionelle genomanwendung

Info

Publication number
DE60034947D1
DE60034947D1 DE60034947T DE60034947T DE60034947D1 DE 60034947 D1 DE60034947 D1 DE 60034947D1 DE 60034947 T DE60034947 T DE 60034947T DE 60034947 T DE60034947 T DE 60034947T DE 60034947 D1 DE60034947 D1 DE 60034947D1
Authority
DE
Germany
Prior art keywords
particles
preparation
screening
virusual
functional genome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60034947T
Other languages
English (en)
Other versions
DE60034947T2 (de
Inventor
Nicholas Hunt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evotec OAI AG
Original Assignee
Evotec OAI AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec OAI AG filed Critical Evotec OAI AG
Publication of DE60034947D1 publication Critical patent/DE60034947D1/de
Application granted granted Critical
Publication of DE60034947T2 publication Critical patent/DE60034947T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4722—G-proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/586—Liposomes, microcapsules or cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
DE60034947T 1999-06-30 2000-06-30 Virusähnliche partikel, vorbereitung und verwendung in screening und funktionelle genomanwendung Expired - Fee Related DE60034947T2 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US14126899P 1999-06-30 1999-06-30
US141268P 1999-06-30
EP99112451 1999-06-30
EP99112451 1999-06-30
EP00106109 2000-03-21
EP00106109 2000-03-21
EP00110363 2000-05-15
EP00110363 2000-05-15
PCT/EP2000/006144 WO2001002551A2 (en) 1999-06-30 2000-06-30 Virus like particles, preparation and use in screening and functional genomics

Publications (2)

Publication Number Publication Date
DE60034947D1 true DE60034947D1 (de) 2007-07-05
DE60034947T2 DE60034947T2 (de) 2008-01-24

Family

ID=56290037

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60034947T Expired - Fee Related DE60034947T2 (de) 1999-06-30 2000-06-30 Virusähnliche partikel, vorbereitung und verwendung in screening und funktionelle genomanwendung

Country Status (7)

Country Link
EP (1) EP1187928B1 (de)
JP (1) JP2003504014A (de)
AT (1) ATE362990T1 (de)
AU (1) AU6267000A (de)
DE (1) DE60034947T2 (de)
DK (1) DK1187928T3 (de)
WO (1) WO2001002551A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763258B2 (en) * 1997-05-20 2010-07-27 The Trustees Of The University Of Pennsylvania Virus-like particles (VLPs) comprising heterologous multiple membrane spanning proteins
US20040014033A1 (en) 1999-06-30 2004-01-22 Evotec Biosystems Ag, A Corporation Of Germany Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
US7476517B2 (en) 1999-06-30 2009-01-13 Evotec Ag Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
US7083958B2 (en) 2000-11-20 2006-08-01 The Board Of Trustees Of The University Of Illinois Membrane scaffold proteins
US7592008B2 (en) 2000-11-20 2009-09-22 The Board Of Trustees Of The University Of Illinois, A Body Corporate And Politic Of The State Of Illinois Membrane scaffold proteins
JP4303468B2 (ja) 2000-11-20 2009-07-29 ザ ボード オブ トラスティーズ オブ ザ ユニバーシテイ オブ イリノイ 膜スカホールドタンパク質
US7622437B2 (en) 2000-11-20 2009-11-24 The Board Of Trustees Of The University Of Illinois Tissue factor compositions and methods
EP1219705B1 (de) * 2000-12-29 2007-11-28 Evotec AG Virus-ähnliche Partikel, ihre Herstellung und ihre Verwendung beim pharmazeutischen Screening und funktionelle Genomanwendungen
US7070978B2 (en) 2001-06-20 2006-07-04 Toudai Tlo, Ltd. Method for expressing and purifying proteins using budded baculovirus
EP1632778A3 (de) 2001-07-09 2006-03-29 Euroscreen S.A. Natürlicher Ligand von gpcr chemr23 und dessen Verwendungen
JP2003052370A (ja) 2001-08-16 2003-02-25 Sentan Kagaku Gijutsu Incubation Center:Kk 発芽バキュロウィルスを用いた機能を有する膜型受容体蛋白質の発現法
JP2005508003A (ja) * 2001-10-30 2005-03-24 バーテックス ファーマシューティカルズ インコーポレイテッド 膜結合レセプターに結合可能な化合物を同定するための方法
JP2003177131A (ja) * 2001-12-11 2003-06-27 Olympus Optical Co Ltd 生物学的な結合親和性を検出する方法
AU2003202542A1 (en) 2002-01-07 2003-07-24 Euroscreen S.A. Ligand for g-protein coupled receptor gpr43 and uses thereof
EP1534344A4 (de) * 2002-06-26 2008-05-28 Advanced Bionutrition Corp Viren und virusartige teilchen für multiple antigen- und target-anzeige
JP2004093527A (ja) * 2002-09-04 2004-03-25 Center For Advanced Science & Technology Incubation Ltd 蛍光共鳴エネルギー転移を用いた蛋白質の分析方法
US8574590B2 (en) 2003-07-30 2013-11-05 Integral Molecular, Inc. Lipoparticles comprising proteins, methods of making, and using the same
US7964196B2 (en) 2004-05-25 2011-06-21 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
US8377691B2 (en) * 2006-01-26 2013-02-19 Integral Molecular, Inc. Lipoparticles comprising ion channels, methods of making and using the same
US8067011B2 (en) 2006-04-07 2011-11-29 Chimeros, Inc. Compositions and methods for treating B-cell malignancies
WO2010120874A2 (en) 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
WO2013034666A2 (en) 2011-09-08 2013-03-14 Chemcom S.A. Novel pheromonal receptor of spodoptera littoralis (lepidoptera, noctuidae) and identification of natural ligand of said receptor and uses thereof
JP2014527072A (ja) 2011-09-09 2014-10-09 バイオメド リアルティー， エル．ピー． ウイルスタンパク質の集合を制御するための方法および組成物
EP2855510B1 (de) 2012-05-24 2023-06-28 Vib Vzw Protein-protein interaktionsfalle basierend auf virus-ähnliche partikel
HUE036134T2 (hu) 2013-05-31 2018-06-28 Chemcom Sa Izzadságban található karbonsavak érzékelésében részt vevõ szaglószervi receptorok és alkalmazásuk
CN107427574B (zh) 2015-01-09 2022-02-08 阿达尔塔有限公司 Cxcr4结合分子
GB201504859D0 (en) 2015-03-23 2015-05-06 Vib Vzw Viral particle based small molecule-protein interaction trap
CN109069613B (zh) * 2016-04-22 2022-10-04 瓦西尼斯公司 痘病毒胞外包膜病毒颗粒上的整合膜蛋白展示
AU2018379263B2 (en) 2017-12-05 2022-02-24 Chemcom S.A. Olfactory receptor involved in the perception of musk fragrance and the use thereof
JP7491932B2 (ja) * 2018-12-28 2024-05-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 操作されたｂ型肝炎コアポリペプチド
WO2024127321A1 (en) * 2022-12-14 2024-06-20 Ustav Jr Mart Engineered virus-like-particles for targeted capture of membrane proteins

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2708046B2 (ja) * 1986-11-01 1998-02-04 ブリティッシュ バイオテック ファーマシューティカルズ リミテッド 融合タンパク質および粒子
DE768377T1 (de) * 1988-09-02 1998-01-02 Dyax Corp Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
IL106362A (en) * 1992-07-16 1998-12-06 Oxford University A system for launching multiple particle antigens
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
GB9304239D0 (en) * 1993-03-01 1993-04-21 British Bio Technology Viral particles
EP0817854A2 (de) * 1995-03-31 1998-01-14 Wolf, Hans, Prof. Dr. Verfahren zur antigenpräsentation, aufbauend auf retrovirusähnlichen partikeln
JPH11511651A (ja) * 1995-05-10 1999-10-12 イントロヘーネ ベスローテン フェンノートシャップ 遺伝子治療に特に適した改良型レトロウイルスベクター
DE19543553B4 (de) * 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
US8349602B1 (en) * 1996-04-19 2013-01-08 Xenogen Corporation Biodetectors targeted to specific ligands
AU732125B2 (en) * 1996-07-17 2001-04-12 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Infectious papillomavirus pseudoviral particles
AUPO434196A0 (en) * 1996-12-24 1997-01-23 Crown In The Right Of The Queensland Department Of Health, The An improved therapeutic
AU7350798A (en) * 1997-04-29 1998-11-24 Universiteit Utrecht Corona virus-like particles as tools for vaccination and therapy
US6451527B1 (en) * 1997-08-29 2002-09-17 Selective Genetics, Inc. Methods using genetic package display for selecting internalizing ligands for gene delivery
US6171591B1 (en) * 1997-12-08 2001-01-09 Pentamer Pharmaceuticals, Inc. Recombinant nodavirus compositions and methods
WO1999035282A1 (en) * 1998-01-09 1999-07-15 Tvw Telethon Institute For Child Health Research Peptide detection method
GB9806666D0 (en) * 1998-03-27 1998-05-27 Stanley Margaret Antigen preparation and use
EP0960942A3 (de) * 1998-05-20 2000-01-12 Introgene B.V. Zielgerichtete Abgage durch einen Aminosäuretransporter
EP0959135A1 (de) * 1998-05-20 1999-11-24 Introgene B.V. Protein-Display und zielgerichtete Darreichung zum Zellreceptor
WO2000009157A1 (en) * 1998-08-14 2000-02-24 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles

Also Published As

Publication number Publication date
EP1187928B1 (de) 2007-05-23
DK1187928T3 (da) 2007-10-08
JP2003504014A (ja) 2003-02-04
DE60034947T2 (de) 2008-01-24
WO2001002551A3 (en) 2001-11-08
WO2001002551A2 (en) 2001-01-11
ATE362990T1 (de) 2007-06-15
AU6267000A (en) 2001-01-22
EP1187928A2 (de) 2002-03-20

Similar Documents

Publication Publication Date Title
DE60034947D1 (de) Virusähnliche partikel, vorbereitung und verwendung in screening und funktionelle genomanwendung
PT1685243E (pt) Linhas celulares aviárias imortalizadas para a produção de vírus
BR0011499A (pt) Moléculas de ácido nucléico oriundas de plantas e células de,planta transgênicas de trigo e o seu uso para a produção de amido modificado
DE60143192D1 (de) Zellen zur entdeckung von medikamenten
WO2002002783A3 (en) Expression vectors
ATE445386T1 (de) Polymerische parfümpartikel
WO2001019405A3 (de) Magnetische nanoteilchen mit biochemischer wirksamkeit und verfahren zu ihrer herstellung sowie ihre verwendung
DE60142614D1 (de) Inität
WO2003076592A3 (en) Novel method for delivery and intracellular synthesis of sirna molecules
WO2004041398A3 (en) Porous inorganic/organic hybrid materials and preparation thereof
DE69942055D1 (de) Durch Sprengung mit Wasserdampf von Holzausgangsmaterialien erzeugte Bruchstücke, solche Bruchstücke als Aggregat aufweisendes Holzmaterial, ihre Herstellungsverfahren und Maschinen
DE60305438D1 (de) Lyophilisierte pharmazeutische zusammensetzung von propofol
DK1051158T3 (da) Farmaceutiske præparater i form af polymere mikropartikler fremstillet ved ekstrudering og sfæronisering
FR2846657B1 (fr) Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2003087138A3 (en) Methods for identifying polypeptide factors interacting with rna
NO20020367L (no) Konjugater og fremgangsmåter for fremstilling derav, og deres anvendelse for transportering av molekyler via biologiskemembraner
DK1082423T3 (da) Cyclin E2-gener og -proteiner
WO2003020892A3 (en) Bv8 NUCLEIC ACIDS AND POLYPEPTIDES WITH MITOGENIC ACTIVITY
WO2005042566A3 (en) Antiangiogenicpeptides for treating or preventing endometriosis
DE59811437D1 (de) Oxiranyl-triazolinthione und ihre verwendung als mikrobizide
WO2000061551A3 (de) Pyrimidin-2-on derivate als integrinrezeptorliganden
DE60037263D1 (de) Virus-ähnliche Partikel, ihre Herstellung und ihre Verwendung beim pharmazeutischen Screening und funktionelle Genomanwendungen
ATE321768T1 (de) Linker-nucleosid, seine herstellung und verwendung
DE60334097D1 (de) Methode zur herstellung von viralen partikeln welche eine veränderte zellbindungsaktivität haben und deren verwendungen
WO2004035783A3 (en) Protein complexes of the tumor-necrosis-factor-alpha (tnf-alpha) signalling pathway

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee